Rademikibart
- Generic Name
- Rademikibart
SIM0718 Treatment of Asthma Clinical Study
- Conditions
- Asthma; Eosinophilic
- Interventions
- Drug: SIM0718 injection of placebo
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Simcere Pharmaceutical Co., Ltd
- Target Recruit Count
- 418
- Registration Number
- NCT06488755
- Locations
- 🇨🇳
China Japan Friendship Hospital, Beijing, Beijing, China
A Study to Evaluate the Safety and Efficacy of CBP-201 in Chinese Adult Subjects With Moderate to Severe AD
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Suzhou Connect Biopharmaceuticals, Ltd.
- Target Recruit Count
- 360
- Registration Number
- NCT05905133
- Locations
- 🇨🇳
Connect Investigative Site 03, Guangzhou, Guangdong, China
🇨🇳Connect Investigative Site 34, Nanjing, Jiangsu, China
🇨🇳Connect Investigative Site 41, Beijing, Beijing, China
CBP-201 in Adolescent and Adult Patients With Moderate-to-severe Atopic Dermatitis
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2023-03-21
- Lead Sponsor
- Suzhou Connect Biopharmaceuticals, Ltd.
- Registration Number
- NCT05614817
A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China
- Conditions
- Moderate-to-severe Atopic Dermatitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Suzhou Connect Biopharmaceuticals, Ltd.
- Target Recruit Count
- 330
- Registration Number
- NCT05017480
- Locations
- 🇨🇳
Connect Investigative Site 33, Hefei, Anhui, China
🇨🇳Connect Investigative Site 32, Shijiazhuang, Hebei, China
🇨🇳Connect Investigative Site 47, Beijing, Beijing, China
A Study to Evaluate CBP-201, Rademikibart, in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-03-05
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Suzhou Connect Biopharmaceuticals, Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT04783389
- Locations
- 🇺🇸
Connect Investigative Site 104, Dallas, Texas, United States
🇺🇸Connect Investigative Site 123, Cincinnati, Ohio, United States
🇺🇸Connect Investigative Site 120, Houston, Texas, United States
Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation
- Conditions
- Moderate to Severe Persistent Asthma
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-02-26
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Suzhou Connect Biopharmaceuticals, Ltd.
- Target Recruit Count
- 322
- Registration Number
- NCT04773678
- Locations
- 🇺🇸
Connect Investigative Site 123, Winter Park, Florida, United States
🇺🇸Connect Investigative Site 147, Toledo, Ohio, United States
🇨🇳Connect Investigative Site 217, Ningbo, Zhejiang, China
A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis
- Conditions
- Moderate-to-severe Atopic Dermatitis
- Interventions
- Drug: placebo
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Suzhou Connect Biopharmaceuticals, Ltd.
- Target Recruit Count
- 226
- Registration Number
- NCT04444752
- Locations
- 🇺🇸
Connect Investigative Site 318, Sherman Oaks, California, United States
🇺🇸Connect Investigative Site 323, San Luis Obispo, California, United States
🇺🇸Connect Investigative Site 332, Coral Gables, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.